vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and LCNB CORP (LCNB). Click either name above to swap in a different company.
LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $13.8M, roughly 1.7× Gossamer Bio, Inc.). LCNB CORP runs the higher net margin — 23.7% vs -342.3%, a 366.0% gap on every dollar of revenue. On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs 5.1%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
GOSS vs LCNB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $23.9M |
| Net Profit | $-47.2M | $5.7M |
| Gross Margin | — | — |
| Operating Margin | -333.6% | 29.2% |
| Net Margin | -342.3% | 23.7% |
| Revenue YoY | 47.1% | 5.1% |
| Net Profit YoY | -43.0% | -7.6% |
| EPS (diluted) | $-0.21 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $23.9M | ||
| Q3 25 | $13.3M | $23.8M | ||
| Q2 25 | — | $22.8M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | — | $22.7M | ||
| Q3 24 | — | $21.4M | ||
| Q2 24 | $95.8M | $19.3M | ||
| Q1 24 | $0 | $17.8M |
| Q4 25 | $-47.2M | $5.7M | ||
| Q3 25 | $-48.2M | $6.9M | ||
| Q2 25 | — | $5.9M | ||
| Q1 25 | — | $4.6M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $4.5M | ||
| Q2 24 | $49.2M | $925.0K | ||
| Q1 24 | $-41.9M | $1.9M |
| Q4 25 | -333.6% | 29.2% | ||
| Q3 25 | -369.4% | 35.6% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 25.6% | ||
| Q4 24 | — | 32.9% | ||
| Q3 24 | — | 24.9% | ||
| Q2 24 | 54.3% | 4.9% | ||
| Q1 24 | — | 12.5% |
| Q4 25 | -342.3% | 23.7% | ||
| Q3 25 | -362.7% | 29.1% | ||
| Q2 25 | — | 26.0% | ||
| Q1 25 | — | 21.4% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | 51.4% | 4.8% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | $-0.21 | $0.40 | ||
| Q3 25 | $-0.21 | $0.49 | ||
| Q2 25 | — | $0.41 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | — | $0.44 | ||
| Q3 24 | — | $0.31 | ||
| Q2 24 | $0.22 | $0.07 | ||
| Q1 24 | $-0.19 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | $21.6M |
| Total DebtLower is stronger | — | $104.4M |
| Stockholders' EquityBook value | $-122.8M | $273.9M |
| Total Assets | $172.2M | $2.2B |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.9M | $21.6M | ||
| Q3 25 | $180.2M | $35.9M | ||
| Q2 25 | — | $49.8M | ||
| Q1 25 | — | $37.7M | ||
| Q4 24 | — | $35.7M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | $354.5M | $34.9M | ||
| Q1 24 | $244.4M | $33.0M |
| Q4 25 | — | $104.4M | ||
| Q3 25 | — | $104.7M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $104.6M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $155.7M | ||
| Q2 24 | — | $162.2M | ||
| Q1 24 | — | $162.6M |
| Q4 25 | $-122.8M | $273.9M | ||
| Q3 25 | $-82.3M | $269.9M | ||
| Q2 25 | — | $263.5M | ||
| Q1 25 | — | $258.7M | ||
| Q4 24 | — | $253.0M | ||
| Q3 24 | — | $253.2M | ||
| Q2 24 | $81.5M | $245.2M | ||
| Q1 24 | $26.7M | $233.7M |
| Q4 25 | $172.2M | $2.2B | ||
| Q3 25 | $208.8M | $2.2B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | $373.4M | $2.4B | ||
| Q1 24 | $259.4M | $2.3B |
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.66× | ||
| Q1 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $34.4M |
| Free Cash FlowOCF − Capex | — | $33.4M |
| FCF MarginFCF / Revenue | — | 140.2% |
| Capex IntensityCapex / Revenue | 0.0% | 4.0% |
| Cash ConversionOCF / Net Profit | — | 6.08× |
| TTM Free Cash FlowTrailing 4 quarters | — | $54.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.3M | $34.4M | ||
| Q3 25 | $-36.2M | $14.0M | ||
| Q2 25 | — | $5.5M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $93.2M | ||
| Q3 24 | — | $11.9M | ||
| Q2 24 | $116.3M | $54.9M | ||
| Q1 24 | $-52.3M | $-11.9M |
| Q4 25 | — | $33.4M | ||
| Q3 25 | — | $13.7M | ||
| Q2 25 | — | $5.2M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $89.4M | ||
| Q3 24 | — | $10.5M | ||
| Q2 24 | — | $53.8M | ||
| Q1 24 | — | $-12.8M |
| Q4 25 | — | 140.2% | ||
| Q3 25 | — | 57.4% | ||
| Q2 25 | — | 23.0% | ||
| Q1 25 | — | 10.0% | ||
| Q4 24 | — | 394.0% | ||
| Q3 24 | — | 49.0% | ||
| Q2 24 | — | 278.6% | ||
| Q1 24 | — | -71.8% |
| Q4 25 | 0.0% | 4.0% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 16.7% | ||
| Q3 24 | — | 6.7% | ||
| Q2 24 | 0.0% | 5.9% | ||
| Q1 24 | — | 4.8% |
| Q4 25 | — | 6.08× | ||
| Q3 25 | — | 2.02× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 15.23× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | 2.36× | 59.35× | ||
| Q1 24 | — | -6.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
